Title: Shaping the future of pharmaceutical technology

Abstract:

The outbreak of chronic diseases such as COVID-19 has made a renewed call for providing urgent healthcare facilities to the citizens across the globe. Pharmaceutical technology is defined as an interdisciplinary field combining pharmacy, biotechnology and engineering. It deals with the manufacture and handling of new drugs as well as the instrumentation of medical devices that are used for diagnostic and treatment of patients. An increasing number of pharmaceutical firms – and, indeed, medical device companies are partnering and integrating with the technology industry. This talk looks ahead to a 2030 beyond the COVID-19 pandemic scenario to examine the trends revolutionizing the sector; trends that are expected to have dramatic impacts. Adopting cutting-edge technologies can play a vital role in the digital revolution of the pharmaceutical industry. Though capturing this opportunity requires identifying the right initiatives. However, it’s not that easy to determine what initiatives to take to scale up and how, as they are still blurry to visualize what digital success will look like in ten years from now. In this talk, we will try to put the spotlight on where digital technology will drive the most value in the pharmaceutical industry, this may help guiding as well as building a strategy for digital success in the pharmaceutical industry. Starting with some trending technologies that are already changing and contributing more to reshape the pharmaceutical industry. Technologies like Artificial Intelligence, Machine Learning, AR-VR, Digital Apps, The Internet of Things, Blockchain, 3D printers use in drugs manufacturing, Organ-on-Chips are among the innovations that are starting to transform the pharmaceutical industry.

Biography:

Khulood A is a forward-leaning innovative product manager, informatics and user experience research expert, a research affiliate at MIT, and climate change scientist with 15 + years of experience working in the USA, UK, and Saudi Arabia in research, leadership, project management, strategic planning, digital transformation, and coaching as evidenced by 12 publications and three automated systems designs related to human services, healthcare, and climate change

Title: Comparative analysis and identification of spike’s novel mutations in three major waves of Iranian COVID -19 samples

Abstract:

Spike, the glycosylated surface protein of coronavirus, is the critical player in receptor binding, membrane fusion, and virus entry into the host cells. Spike contains neutralizing antibodies epitope and is the primary target for immune recognition; therefore, it is the main target of most designed vaccines and drugs in SARS-CoV-2. Mutations in this region are one of the virus's highlighted immune escape mechanisms, requiring deeper insight. Hence, in this study, we investigated the variability and mutations of the spike protein isolated from 72 COVID-19 patients from three waves of disease in Iran. The extracted RNAs from nasopharyngeal samples of patients with COVID-19 infection were subjected to cDNA synthesis and PCR in three overlapping fragments. The PCR products f each patient were assembled and sequenced. Analysis of 72 assembled sequences identified 46 SNPs, including 23 that produce amino acid changes. Among the amino acid changes, D614G mutation has the highest frequency in the disease's second and third wave samples

Biography:

Ahangarzed who was appointed as Director SKIMS during the year 2016 has in the past times served as Professor & Head, Department of Cardiac Surgery. Chief Executive Officer, North Eastern Indira Gandhi Regional Institute Of Health & Medical Sciences, Shillong, Meghalaya.

Title: E-BABE-Encyclopedia of bioanalytical methods for bioavailability and bioequivalence studies of pharmaceuticals

Abstract:

Encyclopedia of Bioanalytical Methods for Bioavailability and Bioequivalence Studies of Pharmaceuticals (E-BABE): It is a unique encyclopedia involving bioanalytical methods for bioavailability and bioequivalence (BA/BE) studies of pharmaceuticals for suitable method selection with thousands of combinations and searches against these methods. Most scrutinized literature was collected from different sources including PubMed. This database has been curetted using published methods for all most all pharmaceuticals. Required information for regular method development/validation such as IUPAC name, structure, solubility, chromatographic conditions, instrumentation information like HPLC, LCMS detection parameters, sample preparations, recovery details, limit of detection and limit of quantification, Tmax, Cmax etc., for routine application in BA/BE studies of pharmaceuticals was incorporated including official pharmacopeias information such as European Pharmacopeia, Japan Pharmacopeia and US Pharmacopeia. Database includes drug based bioanalytical methods covering most required fields and external database links of important drug portals such as drug bank, Rxlist, MEDLINE plus, KEGG Drug ID, KEGG Compound ID, Merck manual, PubChem compound ID, PubChem substance ID and USFDA. Searching/querying the database is through drug name, chemical formula or structural search by smiles format. Keen selections of bioanalytical methods for pharmaceutical analysis or regular quality control are also possible with E-BABE. E-BABE was built understanding the needs of pharmaceutical industry and laboratories including CROs working on BA/BE studies. Presently it has nearly of 5,000 methods and it will be updated regularly. (Up to 250 words)

Biography:

Aarti suryakar has completed his PhD at the age of 25 years from Andhra University and postdoctoral studies from Stanford University School of Medicine. He is the director of a premier Bio-Soft service organization. He has published more than 25 papers in reputed journals and has been serving as an editorial board member of repute. (Up to 100 words)